Disclosures. The Challenges Facing Proton Beam Therapy and Opportunities. Minesh P Mehta, MBChB, FASTRO

Size: px
Start display at page:

Download "Disclosures. The Challenges Facing Proton Beam Therapy and Opportunities. Minesh P Mehta, MBChB, FASTRO"

Transcription

1 Minesh P Mehta, MBChB, FASTRO The Challenges Facing Proton Beam Therapy and Opportunities Disclosures Consultant: Varian, IBA, Agenus, Remedy, Insys DSMB: Monteris Current as of October

2 The Challenges Facing Proton Therapy Introduction An uneven playing field: shifting the goalposts Do we have equipoise for randomized trials? Benefits are delayed far too delayed The cost debate: payors, legislators Opportunities Major Ways of Treating Cancer Surgery, Chemotherapy and Radiation Therapy Radiation Therapy: Photons ( X-rays ) or PROTONS 2

3 Protons Stop, Unlike Photons Maximize Tumor Dose and Spare Healthy Tissue Therapeutic Index Radiotherapy outcomes are a function of Maximal tumor control through delivery of highest safe and necessary dose to the tumor, and Minimal normal tissue complications by reducing dose to normal tissues Proton therapy affords the best dosimetric advantages in this context Primarily due to their physical characteristics of essentially having no to minimal exit dose 3

4 Our Daily Job: A or B? A B The Challenges Facing Proton Beam Therapy An uneven playing field: Shifting the goalposts 4

5 Historic Evolution of RT 1895: X-rays first used to Rx Ca 1950 s: Co-60 radiators 1960s: Early Linac development : level? Blocking techniques for beam contouring 1980s: CT in RT planning: level? 1990s: MLCs, 3D CRT: level? 2000: IMRT, 4D RT, SBRT: level? 2000+: IGRT, Adaptive RT: level? None of these advances are based on randomized trials We accept dosimetric superiority every day 5

6 The Challenges Facing Proton Beam Therapy Do we have equipoise for a randomized trial? Chordoma: Results Mayo (Krishnan, Neurosurg, 2005): 32% 5Y LC with surgery + 3D CRT + GK SRS (n = 25); 10% symptomatic temporal lobe injury PSI, Switzerland (Ares, IJROBP, 2009): 81% 5Y LC with surgery + scanning PBT (n = 42); 6% symptomatic temporal lobe injury MGH (Munzenrider, StrahlentherOnkol, 1999): 73% 5 Y LC with surgery + PBT; 8% symptomatic temporal lobe injury With such large differences for a tumor that kills, would you want to be randomized? 6

7 Equipoise: The Parachute Story Hazardous Journeys Hazardous Journeys: Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials: BMJ 2003;327:1459 As with many interventions intended to prevent ill health, the effectiveness of parachutes has not been subjected to rigorous evaluation by using randomised controlled trials. Advocates of evidence based medicine have criticisedthe adoption of interventions evaluated by using only observational data. We think that everyone might benefit if the most radical protagonists of evidence based medicine organisedand participated in a double blind, randomised, placebo controlled, crossover trial of the parachute. 7

8 The Challenges Facing Proton Beam Therapy Benefits are delayed far too delayed Protons Lower Risk of 2 nd Cancer: SEER Matched Comparison MGH 2 nd cancer study (Chung, IJROBP,2008): 503 patients treated with protons matched with 1,591 SEER registry photon patients 2 nd cancers: 12.8% with photons, 6.4% with protons (adjusted HR = 2.73; 95% CI = , p<.0001) Absolute reduction of 50% The timeline on this is of course years to decades 8

9 Growth Hormone after conformal radiation therapy for Brain Tumors Merchant et al JCO 2011 IQ Craniopharyngioma (ages 5 9) 9

10 Cardiac Toxicity - Myocardial infarction - Coronary revascularization tx - Death from ischemic heart disease - Cardiac morbidity increases 7.4% with each extra Gy. - There is no safe cardiac dose Darby et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. NEJM 2013 Protons for Breast Cancer PMRT Photons/Electrons Photons Protons Courtesy of Shannon MacDonald, MD - MGH Phase III Randomized Breast Ca Trial >1700 patients, protons vs photons, funded by PCORI 10

11 The Challenges Facing Proton Beam Therapy The Cost Debate, Payors, Legislators Protons in the News: $ One news focus is cost. Reality check: Proton facility construction is more expensive in the short run, estimated at $17m per room in a 5 room center. Lifespan of 30 years Long term: High-end Linaccost per room is estimated at $3-4m with a lifespan of 6-7 years, resulting in similar cost outlay over 30 years 11

12 Medulloblastoma Swedish CER Lundkvist, Cancer, 2005 found the lowest lifetime costs for medulloblastoma with protons CRT PBT Fold difference Initial cost $5,622 $13,552 X 2.5 Cost of treating adverse events $44,905 $5,613 X 8 Total costs $50,527 $19,165 X 2.6 What would you choose for your child, irrespective of cost or level of evidence? 100 Pediatric Example: Proton High dose to target, no exit dose Pediatric Example: Photon Dose outside target, could damage normal tissue 12

13 Oregon: Death with Dignity 2/25/15: Oregon Health Evidence Review Commission issues guidance for PBT. Propose an extremely restrictive position: coverage should NOT be provided for pediatric malignancies. Guidances/Proton-Beam-Draft pdf Oregon: Death without Dignity Oklahoma: Leveling the Playing Field 2/19/15: OK house of Representatives passes HB A health benefit plan that. provides coverage for Ca therapy shall be prohibited from holding PBT to a higher standard of clinical evidence for medical policy benefit coverage decisions than the health plan requires for coverage of any other radiation therapy treatment. _id=1602 The entire Insurance Committee of the House of Representatives was treated to a nice lunch by BlueCross/BlueShield just before the vote on whether the Committee would pass the bill onto the full House for consideration. 13

14 Opportunities Exploit Biology Decrease long-term toxicities Decrease acute toxicities NRG BN001: Phase IIR Trial of Hypofractionated Dose-escalated Proton Beam Vs. Std Photon Irradiation With Concomitant and Adjuvant Temozolomide in Newly Diagnosed GBM 28 14

15 Protons Lower the Irradiated Volume IMXT -SIB IMPT -SIB Isodosecomparison of simultaneous integrated boost (SIB) and dose escalation using IMXT and IMPT. The proton approach allows better tumor tissue coverage while sparing more uninvolved structures, and possibly causing less lymphopenia. Images: Anita Mahajan 29 CD4 Counts vs. Survival in GBM Data from Johns Hopkins: Survival in GBM patients by CD4 count 15

16 Cardiac Toxicity - Myocardial infarction - Coronary revascularization tx - Death from ischemic heart disease - Cardiac morbidity increases 7.4% with each extra Gy. - There is no safe cardiac dose Darby et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. NEJM 2013 Protons for Breast Cancer PMRT Photons/Electrons Photons Protons Courtesy of Shannon MacDonald, MD - MGH Phase III Randomized Breast Ca Trial >1700 patients, protons vs photons, funded by PCORI 16

17 Gastrostomy Tubes by >50% With IMPT Case-control study, matched on based on unilateral vsbilateral therapy, tonsil vsbot primary, T-category, N-category, concurrent chemo, induction chemo, smoking status, sex and age. 26 IMPT cases precisely matched to 26 IMRT. Gastrostomy tubes needed in 5 (19%) IMPT vs. 12 (46%) IMRT cases (P <0.039). IMPT = less G3 dysphagia vs. IMRT. Phase 3 randomized trial is ongoing. S.J. Frank, et al: ASTRO How many extra intra-oral x-ray equivalents is IMRT over IMPT? Courtesy of Steven Frank 17

18 Slide 33 1 change "LET (1.1)" to "RBE (>1.1)" Vinai Gondi, 1/27/ removed the pubmed website link and included reference below also would consider changing text of "DSBs" to "double-strand breaks" if it fits Vinai Gondi, 1/27/2013

19 How many intra-oral x-rays is 25 Gy? ,000,000 Courtesy of Steven Frank H-N Phase II/III Randomized Trial Oropharyngeal Cancer - IMPT vs IMRT Eligibility 1) Stage III-IV oropharyngeal cancer 2) Squamous cell carcinoma 3) ECOG<2 4) Target volume delineation R A N D O M I Z A T I O N IMPT (70 Gy(RBE)) Chemotherapy (locally advanced disease) Treatment 33 days PROs Recovery 10 wks IMRT (70 Gy) Chemotherapy (locally advanced disease) Restaging No Surgery Surgery Follow-up PROs Q3 mo Follow-up PROs Q3 mo Frank PI Trial Activated Sept

20 You Can Only Go Home After the Sun Sets Spot Scanning 19

Hot topics in Radiation Oncology for the Primary Care Providers

Hot topics in Radiation Oncology for the Primary Care Providers Hot topics in Radiation Oncology for the Primary Care Providers Steven Feigenberg, MD Professor Chief, Thoracic Oncology Vice Chair of Clinical Research April 19, 2018 Disclosures NONE 2 Early Stage Disease

More information

Particle (proton) Therapy Randomized trials vs. Prospective registry. Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology

Particle (proton) Therapy Randomized trials vs. Prospective registry. Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology Particle (proton) Therapy Randomized trials vs. Prospective registry Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology Should we do randomized trials? Are randomized trials needed

More information

Future Directions in Prostate Cancer: The Case for Protons. John J. Coen, MD Helen & Harry Gray Cancer Center

Future Directions in Prostate Cancer: The Case for Protons. John J. Coen, MD Helen & Harry Gray Cancer Center Future Directions in Prostate Cancer: The Case for Protons John J. Coen, MD Helen & Harry Gray Cancer Center November 14, 2012 Protons and prostate cancer Early proton experience at the MGH The case for

More information

Advances in external beam radiotherapy

Advances in external beam radiotherapy International Conference on Modern Radiotherapy: Advances and Challenges in Radiation Protection of Patients Advances in external beam radiotherapy New techniques, new benefits and new risks Michael Brada

More information

The Current & Future State of Particle Therapy

The Current & Future State of Particle Therapy The Current & Future State of Particle Therapy The MD Anderson Proton Therapy Center- Houston Matthew Palmer, MBA, CMD Chief Operating Officer mpalmer@mdanderson.org The Challenge PlanIQ TM, Courtesy of

More information

11/27/2017. Proton Therapy for Brain Tumors: Hope or Hype? Financial Disclosures. Objectives. None

11/27/2017. Proton Therapy for Brain Tumors: Hope or Hype? Financial Disclosures. Objectives. None Proton Therapy for Brain Tumors: Hope or Hype? 1 Financial Disclosures None 2 Objectives Discuss the rationale and evidence for proton therapy in children and adults Discuss the late effects that can be

More information

Role of protons, heavy ions and BNCT in brain tumors

Role of protons, heavy ions and BNCT in brain tumors Role of protons, heavy ions and BNCT in brain tumors Prof G K Rath Head, NCI (AIIMS-2) Chief, Dr. BRA IRCH, Professor Radiation Oncology All India Institute of Medical Sciences, New Delhi 1 Overview of

More information

The Economic Club of Florida Tallahassee August 13, 2018 Nancy P Mendenhall, MD. The Promise of Protons

The Economic Club of Florida Tallahassee August 13, 2018 Nancy P Mendenhall, MD. The Promise of Protons The Economic Club of Florida Tallahassee August 13, 2018 Nancy P Mendenhall, MD The Promise of Protons The Promise of Protons Cancer and radiation therapy The promise of protons UFHPTI: missions and operation

More information

Particle Therapy for CNS Tumors Anita Mahajan MD MD Anderson Cancer Center PTCOG, Shanghai June 10, 2014

Particle Therapy for CNS Tumors Anita Mahajan MD MD Anderson Cancer Center PTCOG, Shanghai June 10, 2014 Particle Therapy for CNS Tumors Anita Mahajan MD MD Anderson Cancer Center PTCOG, Shanghai June 10, 2014 TCP/NTCP (%) The Potential for Protons in the CNS 10 0 Increase Tumor Control Increase TCP increased

More information

Demands and Perspectives of Hadron Therapy

Demands and Perspectives of Hadron Therapy Demands and Perspectives of Hadron Therapy Alexander Lin, M.D. Assistant Professor University of Pennsylvania Direction of Operations Roberts Proton Therapy Center Disclosures Teva Pharmaceuticals: Advisory

More information

Disclosures. Proton therapy advantages. Why are comparing therapies difficult? Proton Therapy for Low Risk Prostate Cancer

Disclosures. Proton therapy advantages. Why are comparing therapies difficult? Proton Therapy for Low Risk Prostate Cancer Proton Therapy for Low Risk Prostate Cancer Disclosures No relevant financial disclosures This presentation will not discuss off-label or investigational treatments Andrew K. Lee, MD, MPH Associate Professor

More information

NCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) BONE (Version , 03/28/18)

NCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) BONE (Version , 03/28/18) BONE (Version 2.2018, 03/28/18) NCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) Radiation Therapy Specialized techniques such as intensity-modulated RT (IMRT); particle beam RT with protons, carbon ions,

More information

Future of Radiation Therapy

Future of Radiation Therapy Future of Radiation Therapy JP Morgan Healthcare Conference January 12, 2016 Deepak Khuntia, MD, VP of Medical Affairs Patrick Kupelian, MD, VP of Clinical Affairs Cancer as a cause of death CANCER TREATMENT

More information

Ion Beam Therapy should we prioritise research on helium beams?

Ion Beam Therapy should we prioritise research on helium beams? Ion Beam Therapy should we prioritise research on helium beams? Stuart Green Medical Physics University Hospital Birmingham NHS Trust Follow-up from the EUCARD2 workshop, ION Beam Therapy: Clinical, Scientific

More information

Proton- Radiotherapy:

Proton- Radiotherapy: Proton- Radiotherapy: Future of Medical Indications and Treatment Concepts Eugen B. Hug and Ralf A. Schneider HUG 11/07 The emerging role of Proton Radiotherapy in the framework of modern Photon-RT 2000

More information

8/4/2016. Effect of underdosage and overdosage. Photon versus Proton Therapy: Have we reached the limit? Effect. Tumor Dose.

8/4/2016. Effect of underdosage and overdosage. Photon versus Proton Therapy: Have we reached the limit? Effect. Tumor Dose. Effect 8/4/2016 Photon versus Proton Therapy: Have we reached the limit? American Association of Medical Physics Annual Meeting Washington, DC Stephen M Hahn August 4, 2016 Effect of underdosage and overdosage

More information

Locally advanced disease & challenges in management

Locally advanced disease & challenges in management Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, February 2018 Locally advanced disease & challenges in management Carien Creutzberg Radiation Oncology, Leiden

More information

DOES RADIOTHERAPY TECHNIQUE / DOSE / FRACTIONATION REALLY MATTER? YES

DOES RADIOTHERAPY TECHNIQUE / DOSE / FRACTIONATION REALLY MATTER? YES DOES RADIOTHERAPY TECHNIQUE / DOSE / FRACTIONATION REALLY MATTER? YES Marco Krengli Radiotherapy, Department of Translational Medicine, University of Piemonte Orientale A. Avogadro THE STANDARD OF CARE

More information

FROM ICARO1 TO ICARO2: THE MEDICAL PHYSICS PERSPECTIVE. Geoffrey S. Ibbott, Ph.D. June 20, 2017

FROM ICARO1 TO ICARO2: THE MEDICAL PHYSICS PERSPECTIVE. Geoffrey S. Ibbott, Ph.D. June 20, 2017 FROM ICARO1 TO ICARO2: THE MEDICAL PHYSICS PERSPECTIVE Geoffrey S. Ibbott, Ph.D. June 20, 2017 1 DISCLOSURES My institution holds Strategic Partnership Research Agreements with Varian, Elekta, and Philips

More information

Clinical experience with TomoDirect System Tangential Mode

Clinical experience with TomoDirect System Tangential Mode Breast Cancer Clinical experience with TomoDirect System Tangential Mode European Institute of Oncology Milan, Italy Disclosure & Disclaimer An honorarium is provided by Accuray for this presentation The

More information

Recent Advances in Breast Radiotherapy

Recent Advances in Breast Radiotherapy Recent Advances in Breast Radiotherapy Dr Anna Kirby Consultant Clinical Oncologist 2 The Royal Marsden Overview: Key innovations 1. 2D to 3D planning 2. Hypofractionation 3. Intensity modulated radiotherapy

More information

Radiation Therapy 2013 The Role of Protons. Bob Gaston, D.O.

Radiation Therapy 2013 The Role of Protons. Bob Gaston, D.O. Radiation Therapy 2013 The Role of Protons Bob Gaston, D.O. Disclosures Oklahoma ProCure Treatment Center Radiation Medicine Associates Goal of Radiation Therapy Increase the Therapeutic Ratio Therapeutic

More information

Implementation of advanced RT Techniques

Implementation of advanced RT Techniques Implementation of advanced RT Techniques Tibor Major, PhD National Institute of Oncology Budapest, Hungary 2. Kongres radiološke tehnologije, Vukovar, 23-25. September 2016. Current RT equipments at NIO,

More information

The role of chemoradiotherapy in GE junction and gastric cancer. Karin Haustermans

The role of chemoradiotherapy in GE junction and gastric cancer. Karin Haustermans The role of chemoradiotherapy in GE junction and gastric cancer Karin Haustermans Overview Postoperative chemoradiotherapy Preoperative chemoradiotherapy Palliative radiation Technical aspects Overview

More information

Overview of Advanced Techniques in Radiation Therapy

Overview of Advanced Techniques in Radiation Therapy Overview of Advanced Techniques in Radiation Therapy Jacob (Jake) Van Dyk Manager, Physics & Engineering, LRCP Professor, UWO University of Western Ontario Acknowledgements Glenn Bauman Jerry Battista

More information

Ablative Radiation Therapy For Inoperable Cholangiocarcinoma. Christopher H. Crane, M.D. Program Director, GI Section Department of Radiation Oncology

Ablative Radiation Therapy For Inoperable Cholangiocarcinoma. Christopher H. Crane, M.D. Program Director, GI Section Department of Radiation Oncology Ablative Radiation Therapy For Inoperable Cholangiocarcinoma Christopher H. Crane, M.D. Program Director, GI Section Department of Radiation Oncology Facts about radiation treatment High doses (2x the

More information

Radiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK

Radiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK Lead Group Log Radiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK Cervical Cancer treatment Treatment planning should be made on a multidisciplinary

More information

Treatment Planning for Skull Base Tumors PTCOG 52, June 2013

Treatment Planning for Skull Base Tumors PTCOG 52, June 2013 Treatment Planning for Skull Base Tumors PTCOG 52, June 2013 Judy Adams CMD Hanne Kooy Ph.D, Norbert Liebsch MD Department of Radiation Oncology Massachusetts General Hospital Chordomas and Chondrosarcomas

More information

Accuracy Requirements and Uncertainty Considerations in Radiation Therapy

Accuracy Requirements and Uncertainty Considerations in Radiation Therapy Departments of Oncology and Medical Biophysics Accuracy Requirements and Uncertainty Considerations in Radiation Therapy Introduction and Overview 6 August 2013 Jacob (Jake) Van Dyk Conformality 18 16

More information

Sarcoma and Radiation Therapy. Gabrielle M Kane MB BCh EdD FRCPC Muir Professorship in Radiation Oncology University of Washington

Sarcoma and Radiation Therapy. Gabrielle M Kane MB BCh EdD FRCPC Muir Professorship in Radiation Oncology University of Washington Sarcoma and Radiation Therapy Gabrielle M Kane MB BCh EdD FRCPC Muir Professorship in Radiation Oncology University of Washington Objective: Helping you make informed decisions Introduction Process Radiation

More information

NRG Oncology Lung Cancer Portfolio 2016

NRG Oncology Lung Cancer Portfolio 2016 NRG Oncology Lung Cancer Portfolio 2016 Roy Decker, MD PhD Yale Cancer Center Walter J Curran, Jr, MD Winship Cancer Institute of Emory University NRG Oncology Lung Cancer Selected Discussion Stage III

More information

CALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer

CALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000

More information

SBRT in early stage NSCLC

SBRT in early stage NSCLC SBRT in early stage NSCLC Optimal technique and tumor dose Frank Zimmermann Clinic of Radiotherapy and Radiation Oncology University Hospital Basel Petersgraben 4 CH 4031 Basel radioonkologiebasel.ch Techniques

More information

ASTRO econtouring for Lymphoma. Stephanie Terezakis, MD

ASTRO econtouring for Lymphoma. Stephanie Terezakis, MD ASTRO econtouring for Lymphoma Stephanie Terezakis, MD Disclosures No conflicts to disclose 1970 Total Lymphoid Irradiation (TLI) 1995 Involved-Field Radiotherapy (IFRT) 2008 Involved Node Radiotherapy

More information

Clinical Protontherapy Head and Neck cancer

Clinical Protontherapy Head and Neck cancer Clinical Protontherapy Head and Neck cancer Coen Rasch Department of Radiation Oncology Academic Medical Center Amsterdam No disclosures 1 Introduction Proton vsphotonin the literature Model basedindicationprotocol

More information

Treatment Planning & IGRT Credentialing for NRG SBRT Trials

Treatment Planning & IGRT Credentialing for NRG SBRT Trials Treatment Planning & IGRT Credentialing for NRG SBRT Trials Hania Al Hallaq, Ph.D. Department of Radiation & Cellular Oncology The University of Chicago Learning Objectives Explain rationale behind credentialing

More information

The Rise, Fall, and Rise Again of Proton Therapy or Never count out a well-financed therapy

The Rise, Fall, and Rise Again of Proton Therapy or Never count out a well-financed therapy The Rise, Fall, and Rise Again of Proton Therapy or Never count out a well-financed therapy Anthony Zietman MD Shipley Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School

More information

Linac or Non-Linac Demystifying And Decoding The Physics Of SBRT/SABR

Linac or Non-Linac Demystifying And Decoding The Physics Of SBRT/SABR Linac or Non-Linac Demystifying And Decoding The Physics Of SBRT/SABR PhD, FAAPM, FACR, FASTRO Department of Radiation Oncology Indiana University School of Medicine Indianapolis, IN, USA Indra J. Das,

More information

Proton beam therapy: the hope and the hype

Proton beam therapy: the hope and the hype Proton beam therapy: the hope and the hype Professor Karol Sikora Chief Medical Officer Proton Partners International WelshConfed18 Protons The hope and the hype Professor Karol Sikora Chief Medical Officer

More information

Where are we with radiotherapy for biliary tract cancers?

Where are we with radiotherapy for biliary tract cancers? Where are we with radiotherapy for biliary tract cancers? Professor Maria A. Hawkins Associate Professor in Clinical Oncology MRC Group Leader/Honorary Consultant Clinical Oncologist CRUK MRC Oxford Institute

More information

Proton Therapy: Where Are We Now and Where Are We Going? Erin Davis MSN, CRNP, ACNP BC Lead Nurse Practitioner

Proton Therapy: Where Are We Now and Where Are We Going? Erin Davis MSN, CRNP, ACNP BC Lead Nurse Practitioner Proton Therapy: Where Are We Now and Where Are We Going? Erin Davis MSN, CRNP, ACNP BC Lead Nurse Practitioner Genevieve Hollis MSN, CRNP, ANP-BC, AOCN Oncology Nurse Practitioner Advanced Senior Lecturer-B

More information

Stereotactic radiotherapy

Stereotactic radiotherapy Stereotactic radiotherapy Influence of patient positioning and fixation on treatment planning - clinical results Frank Zimmermann Institut für Radioonkologie Universitätsspital Basel Petersgraben 4 CH

More information

Protones/Fotones. Dra. Berta Roth

Protones/Fotones. Dra. Berta Roth Protones/Fotones Dra. Berta Roth The Best in Proton Protect, Therapy, Enhance Today and and Save Tomorrow Lives Advances in Science, biology, physics, imaging allows: More efficient and better tolerated

More information

Questions may be submitted anytime during the presentation.

Questions may be submitted anytime during the presentation. Understanding Radiation Therapy and its Role in Treating Patients with Pancreatic Cancer Presented by Pancreatic Cancer Action Network www.pancan.org August 18, 2014 If you experience technical difficulty

More information

Hypofractionated radiation therapy for glioblastoma

Hypofractionated radiation therapy for glioblastoma Hypofractionated radiation therapy for glioblastoma Luis Souhami, MD, FASTRO Professor McGill University Department of Oncology, Division of Radiation Oncology Montreal Canada McGill University Health

More information

Post-Lumpectomy Radiation Techniques and Toxicities

Post-Lumpectomy Radiation Techniques and Toxicities Post-Lumpectomy Radiation Techniques and Toxicities Laura Willson, MD Abbott Northwestern Hospital Dept. of Radiation Oncology February 2, 2019 Learning Objectives How radiation therapy works Standard

More information

Cardiovascular disease after radiation therapy

Cardiovascular disease after radiation therapy Cardiovascular disease after radiation therapy Giovanna Gagliardi Section of Radiotherapy Physics and Engineering Dept. of Medical Physics Karolinska University Hospital, Stockholm EU Scientific Seminar

More information

Radioterapia nel trattamento del carcinoma mammario e cardiotossicità:

Radioterapia nel trattamento del carcinoma mammario e cardiotossicità: Radioterapia nel trattamento del carcinoma mammario e cardiotossicità: un problema reale, da quantificare, da evitare Bruno Meduri A.O.U. Policlinico di Modena Radioterapia nel trattamento del carcinoma

More information

PEDIATRIC ORBITAL TUMORS RADIOTHERAPY PLANNING

PEDIATRIC ORBITAL TUMORS RADIOTHERAPY PLANNING PEDIATRIC ORBITAL TUMORS RADIOTHERAPY PLANNING ANATOMY ANATOMY CONT ANATOMY CONT. ANATOMY CONT. EYE OF A CHILD Normal tissue tolerance doses (in conventional #) TD 5/5 TD 50/5 Endpoint Gy Gy Optic nerve

More information

San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy

San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy

More information

Disclosures. Overview 8/3/2016. SRS: Cranial and Spine

Disclosures. Overview 8/3/2016. SRS: Cranial and Spine SRS: Cranial and Spine Brian Winey, Ph.D. Department of Radiation Oncology Massachusetts General Hospital Harvard Medical School Disclosures Travel and research funds from Elekta Travel funds from IBA

More information

Disclosures 5/13/2013. Principles and Practice of Radiation Oncology First Annual Cancer Rehabilitation Symposium May 31, 2013

Disclosures 5/13/2013. Principles and Practice of Radiation Oncology First Annual Cancer Rehabilitation Symposium May 31, 2013 Principles and Practice of Radiation Oncology First Annual Cancer Rehabilitation Symposium May 31, 2013 Josh Yamada MD FRCPC Department of Radiation Oncology Memorial Sloan Kettering Cancer Center Disclosures

More information

Partial Breast Irradiation using adaptive MRgRT

Partial Breast Irradiation using adaptive MRgRT Partial Breast Irradiation using adaptive MRgRT Shyama Tetar, radiation-oncologist VUmc Amsterdam 15-12-2017 5 th Vumc SBRT symposium 2017 Current practice Breast conserving treatment (BCT) Breast conserving

More information

Radiation Therapy for breast with Tomotherapy: When?

Radiation Therapy for breast with Tomotherapy: When? Radiation Therapy for breast with Tomotherapy: When? Roberto Orecchia Chair of Radiation Therapy at the University of Milan, IEO & CNAO Quarto incontro italo-francese sul carcinoma mammario: Problematiche

More information

Optimal Management of Isolated HER2+ve Brain Metastases

Optimal Management of Isolated HER2+ve Brain Metastases Optimal Management of Isolated HER2+ve Brain Metastases Eliot Sims November 2013 Background Her2+ve patients 15% of all breast cancer Even with adjuvant trastuzumab 10-15% relapse Trastuzumab does not

More information

De-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist

De-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to

More information

Clinical Aspects of Proton Therapy in Lung Cancer. Joe Y. Chang, MD, PhD Associate Professor

Clinical Aspects of Proton Therapy in Lung Cancer. Joe Y. Chang, MD, PhD Associate Professor Clinical Aspects of Proton Therapy in Lung Cancer Joe Y. Chang, MD, PhD Associate Professor Clinical Service Chief Thoracic Radiation Oncology Lung Cancer Basic Factors No. 1 cancer killer 161,840 patients

More information

Tecniche Radioterapiche U. Ricardi

Tecniche Radioterapiche U. Ricardi Tecniche Radioterapiche U. Ricardi UNIVERSITA DEGLI STUDI DI TORINO Should we always rely on stage? T4N0M0 Stage IIIB T2N3M0 Early stage NSCLC The treatment of choice for early-stage NSCLC is anatomic

More information

ES-SCLC Joint Case Conference. Anthony Paravati Adam Yock

ES-SCLC Joint Case Conference. Anthony Paravati Adam Yock ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar

More information

Simultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer

Simultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer Simultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer Dawn Gintz, CMD, RTT Dosimetry Coordinator of Research and

More information

The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology

The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology (specifically, lung cancer) 2/10/18 Jeffrey Kittel, MD Radiation Oncology, Aurora St. Luke s Medical Center Outline The history

More information

HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium

HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium DISCLOSURE OF INTEREST Nothing to declare HEAD AND NECK CANCER -HPV

More information

Proton Radiation Therapy for Osteosarcomas, Chondrogenic Tumors and Soft Tissue Sarcomas

Proton Radiation Therapy for Osteosarcomas, Chondrogenic Tumors and Soft Tissue Sarcomas Proton Radiation Therapy for Osteosarcomas, Chondrogenic Tumors and Soft Tissue Sarcomas Eugen B. Hug Center for Proton Radiation Therapy Paul Scherrer Institute Is there a place for Proton/Particle Radiotherapy

More information

BRACHYTHERAPY FOR PATIENTS WITH PROSTATE CANCER: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update

BRACHYTHERAPY FOR PATIENTS WITH PROSTATE CANCER: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update BRACHYTHERAPY FOR PATIENTS WITH PROSTATE CANCER: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update Table of Contents Data Supplement 1: Additional Evidence Table(s) Table

More information

Results of Stereotactic radiotherapy for Stage I and II NSCLC Is There a Need for Image Guidance?

Results of Stereotactic radiotherapy for Stage I and II NSCLC Is There a Need for Image Guidance? Results of Stereotactic radiotherapy for Stage I and II NSCLC Is There a Need for Image Guidance? Frank Zimmermann Institute of Radiation Oncolgy University Clinic Basel Petersgraben 4 CH 4031 Basel radioonkologiebasel.ch

More information

Clinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate

Clinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate Clinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate Reference: NHS England B01X09 First published: March 2016 Prepared by NHS England Specialised Services Clinical

More information

Clinical Implications Of Dose Summation And Adaptation

Clinical Implications Of Dose Summation And Adaptation Clinical Implications Of Dose Summation And Adaptation Patrick Kupelian, M.D. Professor and Vice Chair University of California Los Angeles Department of Radiation Oncology pkupelian@mednet.ucla.edu August

More information

Nasopharynx Cancer. 1 Feb Presenters: Dr Raghav Murali-Ganesh (Radiation Oncology Registrar) Dr Peter Luk (Pathology Registrar)

Nasopharynx Cancer. 1 Feb Presenters: Dr Raghav Murali-Ganesh (Radiation Oncology Registrar) Dr Peter Luk (Pathology Registrar) Nasopharynx Cancer 1 Feb 2016 Presenters: Dr Raghav Murali-Ganesh (Radiation Oncology Registrar) Dr Peter Luk (Pathology Registrar) Expert Panels Prof Mo Mo Tin Prof Michael Boyer Dr Raewyn Campbell Prof

More information

Charged-Particle (Proton or Helium Ion) Radiotherapy for Neoplastic Conditions

Charged-Particle (Proton or Helium Ion) Radiotherapy for Neoplastic Conditions Charged-Particle (Proton or Helium Ion) Radiotherapy for Neoplastic Conditions Policy Number: 8.01.10 Last Review: 11/2017 Origination: 11/2006 Next Review: 11/2018 Policy Blue Cross and Blue Shield of

More information

Who Should Know Radiation Oncology Coding?

Who Should Know Radiation Oncology Coding? Why Should We Learn Radiation Oncology Coding? Terry Wu, Ph.D. Chief Physicist Radiation Oncology Department Willis-Knighton Cancer Center Who Should Know Radiation Oncology Coding? Radiation Oncologist

More information

How can we Personalize RT as part of Breast-Conserving Therapy?

How can we Personalize RT as part of Breast-Conserving Therapy? How can we Personalize RT as part of Breast-Conserving Therapy? Jay R. Harris Dana-Farber Cancer Institute (DFCI) Brigham and Women s Hospital (BWH) Harvard Medical School Disclosures I have no COI disclosures

More information

4/8/2016. Disclosures. Virtual Lectures Planning Committee Disclosure Summary. Mayo Medical Laboratories. Learning Objectives

4/8/2016. Disclosures. Virtual Lectures Planning Committee Disclosure Summary. Mayo Medical Laboratories. Learning Objectives Virtual Lectures Planning Committee Disclosure Summary Mayo Medical Laboratories Virtual Lectures 2014 MFMER As a provider accredited by ACCME, College of Medicine, Mayo Clinic (Mayo School of CPD) must

More information

Proton- Radiotherapy: Overview of Clinical Indications

Proton- Radiotherapy: Overview of Clinical Indications Proton- Radiotherapy: Overview of Clinical Indications Eugen B. Hug (with emphasis on indications treated at PSI For comprehensive clinical reviews: ESTRO or PTCOG seminars) HUG 11/07 Complication Free

More information

Stereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms. Overall Clinical Significance 8/3/13

Stereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms. Overall Clinical Significance 8/3/13 Stereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms Jason Sheehan, MD, PhD Departments of Neurosurgery and Radiation Oncology University of Virginia, Charlottesville, VA USA Overall

More information

Quality assurance and credentialing requirements for sites using inverse planned IMRT Techniques

Quality assurance and credentialing requirements for sites using inverse planned IMRT Techniques TROG 08.03 RAVES Quality assurance and credentialing requirements for sites using inverse planned IMRT Techniques Introduction Commissioning and quality assurance of planning systems and treatment delivery

More information

Thierry M. Muanza, MSc, MD, FRCPC,, McGill University Segal Cancer Centre, Jewish General Hospital Montreal, QC, Canada

Thierry M. Muanza, MSc, MD, FRCPC,, McGill University Segal Cancer Centre, Jewish General Hospital Montreal, QC, Canada Thierry M. Muanza, MSc, MD, FRCPC,, McGill University Segal Cancer Centre, Jewish General Hospital Montreal, QC, Canada Déclarations Aucun conflit d intérêt Objectifs d apprentissage Évolution de la radiothérapie

More information

Changing Paradigms in Radiotherapy

Changing Paradigms in Radiotherapy Changing Paradigms in Radiotherapy Marco van Vulpen, MD, PhD Mouldroomdag-2015 Towards the elimination of invasion 1 NIH opinion on the future of oncology Twenty-five years from now,i hope that we won

More information

Hypofractionated Radiotherapy for breast cancer: Updated evidence

Hypofractionated Radiotherapy for breast cancer: Updated evidence 2 rd Bangladesh Breast Cancer Conference, Dhaka, December 2017 Hypofractionated Radiotherapy for breast cancer: Updated evidence Tabassum Wadasadawala Associate Professor of Radiation Oncology Tata Memorial

More information

Potential benefits of intensity-modulated proton therapy in head and neck cancer van de Water, Tara Arpana

Potential benefits of intensity-modulated proton therapy in head and neck cancer van de Water, Tara Arpana University of Groningen Potential benefits of intensity-modulated proton therapy in head and neck cancer van de Water, Tara Arpana IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's

More information

Whole Breast Irradiation: Class vs. Hypofractionation

Whole Breast Irradiation: Class vs. Hypofractionation Whole Breast Irradiation: Class vs. Hypofractionation Kyung Hwan Shin, MD, PhD. Dept. of Radiation Oncology, Seoul National University Hospital 2018. 4. 6. GBCC Treatment Trends of Early Breast Cancer

More information

New Radiation Treatment Modalities in the Treatment of Lung Cancer

New Radiation Treatment Modalities in the Treatment of Lung Cancer New Radiation Treatment Modalities in the Treatment of Lung Cancer David Perry, M.D. Chief, Radiation Oncology Medical Director, CyberKnife Radiosurgery Center Medstar Franklin Square Medical Center Definitions

More information

6/29/2012 WHAT IS IN THIS PRESENTATION? MANAGEMENT OF PRIMARY DEVICES INVESTIGATED MAJOR ISSUES WITH CARDIAC DEVICES AND FROM MED PHYS LISTSERVS

6/29/2012 WHAT IS IN THIS PRESENTATION? MANAGEMENT OF PRIMARY DEVICES INVESTIGATED MAJOR ISSUES WITH CARDIAC DEVICES AND FROM MED PHYS LISTSERVS 6/29/2012 MANAGEMENT OF RADIOTHERAPY PATIENTS WITH IMPLANTED CARDIAC DEVICES Dimitris Mihailidis, PhD., Charleston Radiation Therapy Consultants Charleston, WV 25304 WHAT IS IN THIS PRESENTATION? Types

More information

Radiation Treatment Techniques: Where to find rooms for improvement?

Radiation Treatment Techniques: Where to find rooms for improvement? Radiation Treatment Techniques: Where to find rooms for improvement? Cedric Yu, D.Sc. Carl M. Mansfield, M.D. Professor University of Maryland School of Medicine Founder and CEO, Xcision Medical Systems,

More information

A Dosimetric Comparison of Whole-Lung Treatment Techniques. in the Pediatric Population

A Dosimetric Comparison of Whole-Lung Treatment Techniques. in the Pediatric Population A Dosimetric Comparison of Whole-Lung Treatment Techniques in the Pediatric Population Corresponding Author: Christina L. Bosarge, B.S., R.T. (R) (T) Indiana University School of Medicine Department of

More information

Radiation Therapy in the 21 st Century Competing Technologies

Radiation Therapy in the 21 st Century Competing Technologies Radiation Therapy in the 21 st Century Competing Technologies 2 nd Workshop on Hadron Beam Therapy of Cancer Stephen M. Hahn May 21, 2011 The Evolution of Radiation Therapy 1960 s The First Clinac Standard

More information

Reena Phurailatpam. Intensity Modulated Radiation Therapy of Medulloblastoma using Helical TomoTherapy: Initial Experience from planning to delivery

Reena Phurailatpam. Intensity Modulated Radiation Therapy of Medulloblastoma using Helical TomoTherapy: Initial Experience from planning to delivery Intensity Modulated Radiation Therapy of Medulloblastoma using Helical TomoTherapy: Initial Experience from planning to delivery Reena Phurailatpam Tejpal Gupta, Rakesh Jalali, Zubin Master, Bhooshan Zade,

More information

Radiotherapy and Brain Metastases. Dr. K Van Beek Radiation-Oncologist BSMO annual Meeting Diegem

Radiotherapy and Brain Metastases. Dr. K Van Beek Radiation-Oncologist BSMO annual Meeting Diegem Radiotherapy and Brain Metastases Dr. K Van Beek Radiation-Oncologist BSMO annual Meeting Diegem 24-02-2017 Possible strategies Watchful waiting Surgery Postop RT to resection cavity or WBRT postop SRS

More information

Effectiveness and Safety of Spot Scanning Proton Radiation Therapy for Skull Base Tumors: First Long Term Report of the PSI Experience

Effectiveness and Safety of Spot Scanning Proton Radiation Therapy for Skull Base Tumors: First Long Term Report of the PSI Experience Effectiveness and Safety of Spot Scanning Proton Radiation Therapy for Skull Base Tumors: First Long Term Report of the PSI Experience Carmen Ares, Antony J Lomax, Eugen B Hug, Alessandra Bolsi, Beate

More information

Radiation Therapy: From Fallacy to Science

Radiation Therapy: From Fallacy to Science 27 th Annual Management of Colon and Rectal Diseases 2.23.2019 Radiation Therapy: From Fallacy to Science Hadi Zahra, MD, DABR Radiation Oncologist CHI Health Henry Lynch Cancer Center Assistant Clinical

More information

Update on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver

Update on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Update on Limited Small Cell Lung Cancer Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Objectives - Limited Radiation Dose Radiation Timing Radiation Volume PCI Neurotoxicity

More information

National System for Incident Reporting in Radiation Therapy (NSIR-RT) Taxonomy

National System for Incident Reporting in Radiation Therapy (NSIR-RT) Taxonomy Canadian Partnership for Quality Radiotherapy (CPQR) National System for Incident Reporting in Radiation Therapy (NSIR-RT) National System for Incident Reporting in Radiation Therapy (NSIR-RT) Taxonomy

More information

The Role of Radiation Therapy in the Treatment of Brain Metastases. Matthew Cavey, M.D.

The Role of Radiation Therapy in the Treatment of Brain Metastases. Matthew Cavey, M.D. The Role of Radiation Therapy in the Treatment of Brain Metastases Matthew Cavey, M.D. Objectives Provide information about the prospective trials that are driving the treatment of patients with brain

More information

MEDICAL MANAGEMENT POLICY

MEDICAL MANAGEMENT POLICY PAGE: 1 of 8 This medical policy is not a guarantee of benefits or coverage, nor should it be deemed as medical advice. In the event of any conflict concerning benefit coverage, the employer/member summary

More information

Clinical Results of Carbon Ion Radiotherapy: The Heidelberg Experience

Clinical Results of Carbon Ion Radiotherapy: The Heidelberg Experience Clinical Results of Carbon Ion Radiotherapy: The Heidelberg Experience Stephanie E. Combs, MD Department of Radiation Oncology University of Heidelberg, Germany Carbon ion RT at GSI Active beam delivery

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: charged_particle_radiotherapy 3/12/96 5/2017 5/2018 5/2017 Description of Procedure or Service Charged-particle

More information

ENDPOINTS IN ONCOLOGY- HOW LONG WILL A CANCER PATIENT SURVIVE? DR GUNJAN BAIJAL CONSULTANT RADIATION ONCOLOGY MANIPAL GOA

ENDPOINTS IN ONCOLOGY- HOW LONG WILL A CANCER PATIENT SURVIVE? DR GUNJAN BAIJAL CONSULTANT RADIATION ONCOLOGY MANIPAL GOA ENDPOINTS IN ONCOLOGY- HOW LONG WILL A CANCER PATIENT SURVIVE? DR GUNJAN BAIJAL CONSULTANT RADIATION ONCOLOGY MANIPAL GOA Why so much of cancer today? Times have changed HISTORICAL PERSPECTIVE CANCER as

More information

Stereotactic MR-guided adaptive radiation therapy (SMART) for locally advanced pancreatic tumors

Stereotactic MR-guided adaptive radiation therapy (SMART) for locally advanced pancreatic tumors Stereotactic MR-guided adaptive radiation therapy (SMART) for locally advanced pancreatic tumors Anna Bruynzeel, Radiation Oncologist VU University Medical Center, Amsterdam, The Netherlands Current standard

More information

Proton Radiation Therapy for Osteosarcomas, Chondrogenic Tumors and Soft Tissue Sarcomas

Proton Radiation Therapy for Osteosarcomas, Chondrogenic Tumors and Soft Tissue Sarcomas Proton Radiation Therapy for Osteosarcomas, Chondrogenic Tumors and Soft Tissue Sarcomas Eugen B. Hug Center for Proton Radiation Therapy Paul Scherrer Institute Histologies Osteogenic Tumors Osteogenic

More information

Pancreatic Cancer and Radiation Therapy

Pancreatic Cancer and Radiation Therapy Pancreatic Cancer and Radiation Therapy Why? Is there a role for local therapy with radiation in a disease with such a high rate of distant metastases? When? Resectable Disease Is there a role for post-op

More information

Proton Therapy Dosimetry & Clinical Implementation. Baldev Patyal, Ph.D., Chief Medical Physicist Department of Radiation Medicine

Proton Therapy Dosimetry & Clinical Implementation. Baldev Patyal, Ph.D., Chief Medical Physicist Department of Radiation Medicine Proton Therapy Dosimetry & Clinical Implementation Baldev Patyal, Ph.D., Chief Medical Physicist Department of Radiation Medicine Outline» Proton Therapy Basics» Why Proton Therapy? (Dosimetric Superiority)»

More information